Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
Date: December 3, 2018
Issue #:
1561Summary:
The FDA has approved a new 2.5-mg formulation of
the direct factor Xa inhibitor rivaroxaban (Xarelto–
Janssen) for use in combination with low-dose aspirin
to reduce the risk of major cardiovascular events in
patients with chronic coronary artery disease (CAD)
or peripheral artery disease (PAD). Rivaroxaban is
the first direct oral anticoagulant to be approved for
this indication. It was approve d earlier for prevention
and treatment of deep vein thrombosis (DVT) or
pulmonary embolism (PE) and for prevention of stroke
and systemic embolism in patients with nonvalvular
atrial fibrillation.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Source Type: research
More News: Aspirin | Atrial Fibrillation | Cardiology | Cardiovascular | Drugs & Pharmacology | Heart | Peripheral Vascular Disease (PVD) | Pulmonary Thromboembolism | Stroke | Thrombosis